Medistim ASA
F:MD1

Watchlist Manager
Medistim ASA Logo
Medistim ASA
F:MD1
Watchlist
Price: 23.1 EUR -0.43% Market Closed
Market Cap: €423.1m

Wall St Price Targets

MD1 Price Targets Summary
Medistim ASA

Wall Street analysts forecast MD1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MD1 is 27.96 EUR with a low forecast of 27.06 EUR and a high forecast of 29.43 EUR.

Lowest Forecast
Price Target
27.06 EUR
17% Upside
Average Forecast
Price Target
27.96 EUR
21% Upside
Highest Forecast
Price Target
29.43 EUR
27% Upside
Medistim ASA Competitors:
Price Targets
VIBHA
Vibhavadi Medical Center PCL
6% Upside
NKTX
Nkarta Inc
296% Upside
CBAN
Colony Bankcorp Inc
16% Upside
HZO
MarineMax Inc
-8% Downside
SITM
SiTime Corp
45% Upside
EXLS
Exlservice Holdings Inc
23% Upside

Revenue
Forecast

11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 11%.

Gross Profit
Forecast

12% / Year
Past Growth
11% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
11% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 11%.

Operating Income
Forecast

16% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
16% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 11%.

Pre-Tax Income
Forecast

17% / Year
Past Growth
-31% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
17% / Year
Past Growth
-31% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 17%. The projected CAGR for the next 1 year is -31%.

Net Income
Forecast

18% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
18% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 8%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MD1's stock price target?
Price Target
27.96 EUR

According to Wall Street analysts, the average 1-year price target for MD1 is 27.96 EUR with a low forecast of 27.06 EUR and a high forecast of 29.43 EUR.

What is the Revenue forecast for Medistim ASA?
Projected CAGR
11%

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 11%.

What is the Gross Profit forecast for Medistim ASA?
Projected CAGR
11%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 11%.

What is the Operating Income forecast for Medistim ASA?
Projected CAGR
11%

Over the last 14 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 11%.

What is the Pre-Tax Income forecast for Medistim ASA?
Projected CAGR
-31%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 17%. The projected CAGR for the next 1 year is -31%.

What is the Net Income forecast for Medistim ASA?
Projected CAGR
8%

Over the last 14 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 8%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett